Goodwin hosted its Annual Rare Disease Symposium on March 13, bringing together stakeholders from patient advocacy, biotech, academia, and the FDA to discuss past progress, current challenges, and future opportunities in rare disease drug development. The event highlighted the perspectives of regulators and clinical investigators on past progress, current challenges, and future opportunities in the field. More in AgencyIQ.